These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 19860693)

  • 1. Phosphodiesterase type 5 inhibitors: unmet needs.
    Hatzimouratidis K; Hatzichristou DG
    Curr Pharm Des; 2009; 15(30):3476-85. PubMed ID: 19860693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Looking to the future for erectile dysfunction therapies.
    Hatzimouratidis K; Hatzichristou DG
    Drugs; 2008; 68(2):231-50. PubMed ID: 18197727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphodiesterase type 5 inhibitors: the day after.
    Hatzimouratidis K; Hatzichristou D
    Eur Urol; 2007 Jan; 51(1):75-88; discussion 89. PubMed ID: 16949200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?
    Hatzimouratidis K; Hatzichristou DG
    Drugs; 2005; 65(12):1621-50. PubMed ID: 16060698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors.
    Sommer F; Schulze W
    World J Urol; 2005 Dec; 23(6):385-92. PubMed ID: 16273418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PDE5 inhibitors: are there differences?
    Carson CC
    Can J Urol; 2006 Feb; 13 Suppl 1():34-9. PubMed ID: 16526979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An update on new oral PDE5 inhibitors for the treatment of erectile dysfunction.
    Palit V; Eardley I
    Nat Rev Urol; 2010 Nov; 7(11):603-9. PubMed ID: 21068761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PDE5 inhibitors: considerations for preference and long-term adherence.
    Smith WB; McCaslin IR; Gokce A; Mandava SH; Trost L; Hellstrom WJ
    Int J Clin Pract; 2013 Aug; 67(8):768-80. PubMed ID: 23869678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Impact of the pharmacokinetic properties of PDE5 inhibitors on the dose/sexual intercourse interval].
    Giuliano F; Vicaut E; Jeanpetit Y
    Prog Urol; 2008 Sep; 18(8):536-42. PubMed ID: 18760744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2009 update on phosphodiesterase type 5 inhibitor therapy part 2: updates on optimal utilization for sexual concerns and rare toxicities in this class.
    Shindel AW
    J Sex Med; 2009 Sep; 6(9):2352-64; quiz 2365-6. PubMed ID: 19735356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy of tadalafil once daily in men with erectile dysfunction who demonstrated previous partial responses to as-needed sildenafil, tadalafil, or vardenafil.
    Kim E; Seftel A; Goldfischer E; Baygani S; Burns P
    Curr Med Res Opin; 2015 Feb; 31(2):379-89. PubMed ID: 25455432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphodiesterase type 5 inhibitors: a viable treatment option for lower urinary tract symptoms?
    Hatzimouratidis K
    Expert Opin Investig Drugs; 2009 Mar; 18(3):245-54. PubMed ID: 19243276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphodiesterase 5 inhibitors for erectile dysfunction.
    Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE
    Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic treatment with a type 5 phosphodiesterase inhibitor suppresses apoptosis of corporal smooth muscle by potentiating Akt signalling in a rat model of diabetic erectile dysfunction.
    Park K; Ryu KS; Li WJ; Kim SW; Paick JS
    Eur Urol; 2008 Jun; 53(6):1282-8. PubMed ID: 18243503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of phosphodiesterase type 5 (PDE5) inhibitors.
    Wright PJ
    Int J Clin Pract; 2006 Aug; 60(8):967-75. PubMed ID: 16780568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics, behaviors, and attitudes of men bypassing the healthcare system when obtaining phosphodiesterase type 5 inhibitors.
    Schnetzler G; Banks I; Kirby M; Zou KH; Symonds T
    J Sex Med; 2010 Mar; 7(3):1237-46. PubMed ID: 20136707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PDE5 inhibitors beyond erectile dysfunction.
    Sandner P; Hütter J; Tinel H; Ziegelbauer K; Bischoff E
    Int J Impot Res; 2007; 19(6):533-43. PubMed ID: 17625575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Experience of using three phosphodiesterase type 5 inhibitors in the same period for the treatment of erectile dysfunction].
    Zhang SX; Gao P
    Zhonghua Nan Ke Xue; 2007 Mar; 13(3):226-8. PubMed ID: 17393785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphodiesterase type 5 inhibitors for erectile dysfunction.
    Carson CC; Lue TF
    BJU Int; 2005 Aug; 96(3):257-80. PubMed ID: 16042713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of efficacy and safety of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction].
    Chen Q; Wang N; Yao F; Lu X
    Zhonghua Nan Ke Xue; 2004 Apr; 10(4):302-4. PubMed ID: 15148932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.